Wolfe starts AbbVie at Outperform, says valuation an attractive entry point
Wolfe Research initiated coverage of AbbVie (ABBV) with an Outperform rating and $205 price target The firm noted that AbbVie sounded ...
MedPage Today1d
1 in 5 Adults Report Anxiety, Depression; Esketamine Label Update; Autism Dx Up 175%
The FDA added a warning to the label of esketamine nasal spray (Spravato), noting that long-term cognitive and memory ...
BioSpace1d
AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More
A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an ...
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Positive Outlook on AbbVie: Geoff Meacham’s Buy Rating and Potential of Emraclidine Amid Schizophrenia Trial Challenges
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...
AbbVie Stock Slides on Schizophrenia Drug Study Failure
AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...
Buy, Sell, Or Hold AbbVie Stock?
Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.
STAT2d
Despite setback, AbbVie’s big bet on neuroscience has yet to play out
For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...
thedailyupside3d
Abbvie Shares Sink Following Two Poor Trials
And Cerevel Therapeutics, which had positive early testing results for emraclidine, its drug that aims to treat schizophrenia ...
BioPharma Dive3d
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
Crain's Chicago Business3d
AbbVie tumbles after new schizophrenia drug fails trials
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
Why AbbVie Stock Was Getting Mashed on Monday
Disappointing news from the laboratory weighed on AbbVie (NYSE: ABBV) stock as the trading week kicked off. The company had high hopes for a schizophrenia drug it was developing; however, it did not ...